The Bio-inspired Artificial Pancreas for Type 1 Diabetes Control in the Home: System Architecture and Preliminary Results.
artificial pancreas
automatic insulin delivery
bio-inspired technology
low-power electronics
type 1 diabetes
Journal
Journal of diabetes science and technology
ISSN: 1932-2968
Titre abrégé: J Diabetes Sci Technol
Pays: United States
ID NLM: 101306166
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
pubmed:
15
10
2019
medline:
10
9
2020
entrez:
15
10
2019
Statut:
ppublish
Résumé
Artificial pancreas (AP) technology has been proven to improve glucose and patient-centered outcomes for people with type 1 diabetes (T1D). Several approaches to implement the AP have been described, clinically evaluated, and in one case, commercialized. However, none of these approaches has shown a clear superiority with respect to others. In addition, several challenges still need to be solved before achieving a fully automated AP that fulfills the users' expectations. We have introduced the Bio-inspired Artificial Pancreas (BiAP), a hybrid adaptive closed-loop control system based on beta-cell physiology and implemented directly in hardware to provide an embedded low-power solution in a dedicated handheld device. In coordination with the closed-loop controller, the BiAP system incorporates a novel adaptive bolus calculator which aims at improving postprandial glycemic control. This paper focuses on the latest developments of the BiAP system for its utilization in the home environment. The hardware and software architectures of the BiAP system designed to be used in the home environment are described. Then, the clinical trial design proposed to evaluate the BiAP system in an ambulatory setting is introduced. Finally, preliminary results corresponding to two participants enrolled in the trial are presented. Apart from minor technical issues, mainly due to wireless communications between devices, the BiAP system performed well (~88% of the time in closed-loop) during the clinical trials conducted so far. Preliminary results show that the BiAP system might achieve comparable glycemic outcomes to the existing AP systems (~73% time in target range 70-180 mg/dL). The BiAP system is a viable platform to conduct ambulatory clinical trials and a potential solution for people with T1D to control their glucose control in a home environment.
Sections du résumé
BACKGROUND
Artificial pancreas (AP) technology has been proven to improve glucose and patient-centered outcomes for people with type 1 diabetes (T1D). Several approaches to implement the AP have been described, clinically evaluated, and in one case, commercialized. However, none of these approaches has shown a clear superiority with respect to others. In addition, several challenges still need to be solved before achieving a fully automated AP that fulfills the users' expectations. We have introduced the Bio-inspired Artificial Pancreas (BiAP), a hybrid adaptive closed-loop control system based on beta-cell physiology and implemented directly in hardware to provide an embedded low-power solution in a dedicated handheld device. In coordination with the closed-loop controller, the BiAP system incorporates a novel adaptive bolus calculator which aims at improving postprandial glycemic control. This paper focuses on the latest developments of the BiAP system for its utilization in the home environment.
METHODS
The hardware and software architectures of the BiAP system designed to be used in the home environment are described. Then, the clinical trial design proposed to evaluate the BiAP system in an ambulatory setting is introduced. Finally, preliminary results corresponding to two participants enrolled in the trial are presented.
RESULTS
Apart from minor technical issues, mainly due to wireless communications between devices, the BiAP system performed well (~88% of the time in closed-loop) during the clinical trials conducted so far. Preliminary results show that the BiAP system might achieve comparable glycemic outcomes to the existing AP systems (~73% time in target range 70-180 mg/dL).
CONCLUSION
The BiAP system is a viable platform to conduct ambulatory clinical trials and a potential solution for people with T1D to control their glucose control in a home environment.
Identifiants
pubmed: 31608656
doi: 10.1177/1932296819881456
pmc: PMC6835194
doi:
Substances chimiques
Blood Glucose
0
Hypoglycemic Agents
0
Insulin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1017-1025Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 100921/Z/13/Z
Pays : United Kingdom
Références
Diabetes Care. 2018 Mar;41(3):531-537
pubmed: 29273578
J Diabetes Complications. 2016 Sep-Oct;30(7):1333-8
pubmed: 27288203
Physiol Meas. 2004 Aug;25(4):905-20
pubmed: 15382830
J Diabetes Sci Technol. 2020 Jan;14(1):87-96
pubmed: 31117804
Diabetes Care. 2008 May;31(5):934-9
pubmed: 18252903
J Diabetes Sci Technol. 2012 May 01;6(3):606-16
pubmed: 22768892
J Diabetes Sci Technol. 2015 Nov 17;10(2):405-13
pubmed: 26581881
Diabet Med. 2018 Apr;35(4):450-459
pubmed: 29337384
Diabetes Care. 2017 Dec;40(12):1719-1726
pubmed: 29030383
J Diabetes Sci Technol. 2013 Nov 01;7(6):1621-31
pubmed: 24351189
Diabetes Technol Ther. 2018 Jun;20(S2):S216-S223
pubmed: 29873517
Am J Physiol Endocrinol Metab. 2010 Mar;298(3):E597-601
pubmed: 20009025
Ther Deliv. 2018 Feb;9(2):77-87
pubmed: 29235423
J Diabetes Sci Technol. 2009 Sep 01;3(5):1031-8
pubmed: 20144416
J Diabetes Sci Technol. 2016 May 03;10(3):714-23
pubmed: 26589628
J Diabetes Sci Technol. 2015 Oct 01;9(6):1217-26
pubmed: 26428933
Diabetes Technol Ther. 2019 Jan;21(1):35-43
pubmed: 30547670
Automatica (Oxf). 2016 Sep;71:237-246
pubmed: 27695131
Diabetes Care. 2017 Dec;40(12):1644-1650
pubmed: 28855239
Bioelectron Med. 2018 Nov 7;4:14
pubmed: 32232090
Comput Methods Programs Biomed. 2017 Jul;146:125-131
pubmed: 28688482
BMJ. 2018 Apr 18;361:k1310
pubmed: 29669716
Am J Physiol Endocrinol Metab. 2014 Mar;306(6):E627-34
pubmed: 24425760
Adv Drug Deliv Rev. 2004 Feb 10;56(2):125-44
pubmed: 14741112
IEEE Rev Biomed Eng. 2017;10:44-62
pubmed: 28880188
J Diabetes Sci Technol. 2018 Sep;12(5):1064-1071
pubmed: 29783897
Diabetes Technol Ther. 2018 Oct;20(10):689-692
pubmed: 30160523
J Diabetes Sci Technol. 2013 Jul 01;7(4):941-51
pubmed: 23911175
Diabetes Care. 2017 Jan;40(1):e3
pubmed: 27999006
Diabetes Obes Metab. 2015 May;17(5):468-76
pubmed: 25600304
Sci Transl Med. 2019 Mar 20;11(484):
pubmed: 30894501
Diabetes Care. 2016 Jul;39(7):1175-9
pubmed: 27330126
Diabetes Care. 2018 Jul;41(7):1471-1477
pubmed: 29752345
Curr Opin Endocrinol Diabetes Obes. 2014 Aug;21(4):251-6
pubmed: 24937038
Diabetes Technol Ther. 2014 Sep;16(9):550-7
pubmed: 24801544
J Diabetes Sci Technol. 2013 Nov 01;7(6):1632-43
pubmed: 24351190
Lancet Diabetes Endocrinol. 2017 May;5(5):377-390
pubmed: 28126459